2030, Dosage and Drug Development

Search:

DAY

WEEK

MONTH

YEAR

Select your country:
Sign up | Log in

2030

Dosage

Drug Development

Responsible sourcing and manufacturing: Growing towards a sustainable future with Lonza

Express Pharma

JANUARY 17, 2025

As environmental concerns continue to intensify, the pressure on the pharmaceutical industry to reduce its overall environmental impact, particularly in final dosage forms, is growing proportionately. We have committed to reduce our scope 1 and 2 GHG emissions by 42 per cent (absolute) by the end of 2030 (from a 2021 basis).

Dosage

Dosage Pharmaceutical Manufacturing Packaging Drug Development

WuXi STA opens its first oral solids continuous manufacturing line

European Pharmaceutical Review

JANUARY 4, 2023

WuXi STA , a subsidiary of WuXi AppTec, has announced that its first continuous manufacturing ( CM ) line for oral solids is in operation at its drug product site in Wuxi city, China. A report has estimated that the oral solid dosage (OSD) contract manufacturing market will be valued at $54.7 billion by 2030. Oral solids.

Dosage

Dosage Drug Development

Pharmacist Digest

Responsible sourcing and manufacturing: Growing towards a sustainable future with Lonza

WuXi STA opens its first oral solids continuous manufacturing line

Stay Connected